首页> 外文期刊>Cell stem cell >Targeting the RNA m(6)A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia
【24h】

Targeting the RNA m(6)A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia

机译:靶向RNA m(6)读者YTHDF2选择性地妥协癌症干细胞在急性髓鞘中的白血病中

获取原文
获取原文并翻译 | 示例
       

摘要

Acute myeloid leukemia (AML) is an aggressive clonal disorder of hematopoietic stem cells (HSCs) and primitive progenitors that blocks their myeloid differentiation, generating self-renewing leukemic stem cells (LSCs). Here, we show that the mRNA m(6)A reader YTHDF2 is overexpressed in a broad spectrum of humanAML and is required for disease initiation as well as propagation in mouse and human AML. YTHDF2 decreases the half-life of diverse m(6)A transcripts that contribute to the overall integrity of LSC function, including the tumor necrosis factor receptor Tnfrsf2, whose upregulation in Ythdf2-deficient LSCs primes cells for apoptosis. Intriguingly, YTHDF2 is not essential for normal HSC function, with YTHDF2 deficiency actually enhancing HSC activity. Thus, we identify YTHDF2 as a unique therapeutic target whose inhibition selectively targets LSCs while promoting HSC expansion.
机译:急性髓性白血病(AML)是造血干细胞(HSC)的侵略性克隆疾病,原始祖细胞,阻断它们的骨髓分化,产生自我更新的白血病干细胞(LSCs)。 在这里,我们表明MRNA M(6)读者YTHDF2在广谱的HEAMML中过表达,并且是疾病引发以及小鼠和人AML中的繁殖所必需的。 Ythdf2降低了多样化的M(6)的半衰期,该转录物有助于LSC功能的整体完整性,包括肿瘤坏死因子受体TNFRSF2,其上调在Ythdf2缺陷的LSCs引发细胞中的细胞凋亡。 有趣的是,YTHDF2对正常HSC功能不是必需的,YTHDF2缺乏实际增强HSC活性。 因此,我们将YTHDF2鉴定为独特的治疗目标,其抑制在促进HSC膨胀的同时选择性地靶向LSC。

著录项

  • 来源
    《Cell stem cell》 |2019年第1期|共18页
  • 作者单位

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Manchester Canc Res UK Manchester Inst Leukaemia Biol Lab Manchester M20 4GJ Lancs England;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Queen Mary Univ London Barts Canc Inst Ctr Haematooncol Lab Haematopoiet Stem Cell &

    Leukaemia;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Harvard Med Sch Dept Biol Chem &

    Mol Pharmacol Boston MA 02115 USA;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh Roslin Inst Edinburgh EH25 9RG Midlothian Scotland;

    Univ Tours CNRS LNOx ERL 7001 Tours France;

    Univ Tours CNRS LNOx ERL 7001 Tours France;

    Univ Manchester Canc Res UK Manchester Inst Leukaemia Biol Lab Manchester M20 4GJ Lancs England;

    Harvard Med Sch Dept Biol Chem &

    Mol Pharmacol Boston MA 02115 USA;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

    Univ Edinburgh MRC Ctr Regenerat Med Edinburgh EH16 4UU Midlothian Scotland;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号